Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
Prostate cancer is a common cancer in men; for metastatic disease, it has a 5-year survival rate of 30%. No FDA-approved therapy for castrate-resistant prostate cancer (CRPC) known to improve survival was available until 2004, when based on a significant survival benefit over mitoxantrone, docetaxel...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2012-06-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/339576 |